| (Values in U.S. Thousands) | Dec, 2020 | Dec, 2019 | Dec, 2018 | Dec, 2017 | Dec, 2016 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -520 | 870 | -440 | -1,890 | -2,920 |
| Net Income Growth | -159.77% | +297.73% | +76.72% | +35.27% | +21.08% |
Taxus Cardium Pharmaceuticals Group (CRXM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Taxus Cardium Pharmaceuticals Group Inc. operates as a development stage advanced regenerative therapeutics company. It is focused on the late-stage clinical and commercial development of regenerative medicine therapeutics. The company provides Generx (R) for the treatment of cardiac microvascular insufficiency due to advancing coronary artery disease, and Excellagen (R), for the treatment of chronic non-healing diabetic foot, venous and pressure ulcers. Taxus Cardium Pharmaceuticals Group Inc., formerly known as Cardium Therapeutics, Inc., is headquartered in San Diego, California.
Fiscal Year End Date: 12/31